Pharmaceutical composition containing ghrp-6 to prevent and eliminate fibrosis and other pathological deposits in tissues

a technology of fibrosis and other pathological deposits in tissues, applied in the pharmaceutical industry and medicine, can solve the problems of complex mechanisms mediated by fibrosis establishment, general fatality of long-term fibroses, and fully understood

Inactive Publication Date: 2009-09-03
CENT DE ING GENETICA & BIOTECNOLOGIA
View PDF2 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Mechanisms mediating fibrosis establishment are complex, and remain to be fully comprehended.
Long-term fibroses are generally fatal with no cure available so far.
However, when the damaged is sustained, a misbalance of factors involved in repairing and resolving the problem alters the EM regulation and promotes the excessive synthesis of its components.
In general, all the fibrotic indurations of the liver are incompatible with life (Hepatic Failure.
Even with the sequence of events in the pathogenesis of pulmonary fibrosis well documented, there is little information about the precise mechanisms mediating the main damage.
The deposition process of EM and particularly collagen in the pulmonary parenchyma insidiously deteriorates lung architecture, collapsing bronchioles and alveoli, ultimately becoming dysfunctional and compromising the pulmonary ventilation.
Until now there is no plausible theory of explaining its pathogenesis.
However, fundamental abnormalities in fibroblasts, endothelial cells and cells o...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing ghrp-6 to prevent and eliminate fibrosis and other pathological deposits in tissues

Examples

Experimental program
Comparison scheme
Effect test

example 1

Reverting Hepatic Fibrosis in Rats

[0014]The present experiment was conducted to evaluate the effect of the GHRP-6-based pharmaceutical composition on reverting the hepatic fibrosis in rats. Hepatic fibrosis was induced in male Wistar rats of 250 g of average body weight by ligating the external bile duct. For this purpose, rats were anesthetized with a ketamine / xylazine combination and subjected to laparotomy to expose the common bile duct. The duct was double-ligated with chromium catgut 4-0. After surgery, animals were randomly distributed into 3 experimental groups of 20 rats each: (1) Control placebo group, receiving physiological saline solution, (2) Group receiving the GHRP-6 at a 100 μg / kg dosage, and (3) Group receiving the GHRP-6 at a 400 μg / kg dosage. Treatments were daily administered during three weeks after inducing the fibrosis of the liver parenchyma. All the treatments were started three weeks after the appearance of fibrosis. The follow up of the hepatic damag...

example 2

Reverting Hepatic Fibrosis in Rats

[0017]This experiment was conducted to evaluate the effect of the pharmaceutical composition containing the GHRP-6 on reverting hepatic fibrosis in rats, wherein said hepatic fibrosis was induced by carbon tetrachloride (CCl4). This is a hepatotoxic agent that causes chronic hepatitis and fibrosis after long-term administration. Hepatic fibrosis was induced in male Wistar rats of 250 g of body weight by intraperitoneally administered CCl4 50% / 50% (v / v) in olive oil, twice per week during four weeks. After that time, 25% of the rats were sacrificed and subjected to blood biochemistry and pathological anatomy studies. The process of hepatic fibrosis was demonstrated in all the animals studied. The animals remaining were randomly distributed into three experimental groups of 15 rats each: (1) Control placebo group, receiving physiological saline solution, (2) Group receiving the GHRP-6 at a 100 μg / kg dosage, and (3) Group receiving the GHRP-6 at ...

example 3

[0019]Reverting renal fibrosis of Nephrosclerosis in rats. Third experiment. This experiment was conducted to evaluate the effect of the pharmaceutical composition containing GHRP-6 in reverting renal fibrosis in rats. In this case, the process was induced by sustained administration of the anti-neoplasic agent Doxorubicin (DX) at a 2.5 mg / kg dosage twice a week during 8 weeks. The occurrence of fibrosis deposition in the periportal, peri-bronchial and over the entire renal interstitium with a cystic-nodular pattern was demonstrated by histopathological studies of these organs in 25% of the rat population intoxicated with Doxorubicin. This point forward, DX administration was interrupted and the treatment with the pharmaceutical composition containing the GHRP-6 was started. The treatment was applied once daily at 100 and 400 μg / kg in a volume of 1 ml by the intraperitoneal route, during 4 weeks. The animals remaining were randomly distributed into three experimental groups of 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

Description

FIELD OF TECHNIQUE[0001]The present invention relates to the field of the pharmaceutical industry and medicine, and more precisely to the use of secretagogue peptides that repeatedly administered in a pharmaceutical composition prevent and eliminate pathological depots of fibrotic material in parenchymatous internal tissues, like in the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints and other systemic forms of cutaneous fibrosis of any etiopathogenesis.DESCRIPTION OF THE PRIOR ART[0002]Fibrosis events comprise a group of mono-organic or systemic pathological entities characterized by the abnormal depot of extracellular matrix in parenchyma of almost every internal organ, blood vessels or the skin. They are considered as consequence of complex autoimmune-based events or interstitial responses to prolonged mimicking and inflammatory events. In general, an excess of collagenous material is deposited in the parenchyma by interstitial effector cells or expanded ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/08
CPCA61K38/05A61K38/25A61K38/08A61P1/16A61P11/00A61P13/12A61P17/00A61P17/02A61P19/04A61P21/00A61P25/00A61P25/28A61P27/02A61P27/16A61P43/00
Inventor ACOSTA, JORGE BERLANGACIBRIAN VERA, DANAYDEL BARCO HERRERA, DIANA GARCIAGUILLEN NIETO, GERARDO ENRIQUESUAREZ ALBA, JOSELOPEZ MOLA, ERNESTOSELMAN-HOUSEIN SOSA, MANUELVAZQUEZ CASTILLO, MARIELA
Owner CENT DE ING GENETICA & BIOTECNOLOGIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap